AHA GUIDELINES Bundle (free trial) - Heart Failure

ACC AHA Heart Failure Guidelines 2022 Update

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1461930

Contents of this Issue


Page 79 of 79

Disclaimer is pocket guide attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is pocket guide should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Source Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiolog y/American Heart Association Joint Committee on Clinical Practice Guidelines [published online ahead of print April 1, 2022]. J Am Coll Cardiol. doi: 10.1016/j. jacc.2021.12.012 Copublished in Circulation. doi: 10.1161/CIR.0000000000001063 AHAHF02223 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2022 All rights reserved GuidelineCentral.com Abbreviations AF, atrial fibrillation; AL-CM, immunoglobulin light chain amyloid cardiomyopathy; ATTR-CM, transthyretin amyloid cardiomyopathy; ATTRv, variant transthyretin amyloidosis; ATTRwt, wild- type transthyretin amyloidosis; BNP, B-type natriuretic peptide; CABG, coronary artery bypass gra; CAD, coronary artery disease; CCM, cardiac contractility modulation; CHA 2 DS 2 -VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack [TIA], vascular disease, age 65 to 74 years, sex category; CHF, congestive heart failure; CKD, chronic kidney disease; CMR, cardiovascular magnetic resonance; COVID-19, coronavirus disease 2019; CPET, cardiopulmonary exercise test; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy with defibrillation; CRT-P, cardiac resynchronization therapy with pacemaker; CT, computed tomography; CVD, cardiovascular disease; CVP, central venous pressure; DOAC, direct-acting oral anticoagulants; DPP-4, dipeptidyl peptidase-4; ECG, electrocardiogram; EF, ejection fraction; eGFR, estimated glomerular filtration rate; ERO, effective regurgitant orifice; FDA, U.S. Food and Drug Administration; FLC, free light chain; GDMT, guideline-directed medical therapy; HF, heart failure; HFimpEF, heart failure with improved ejection fraction; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; IFE, immunofixation electrophoresis; LBBB, le bundle branch block; LV, le ventricular; LVAD, le ventricular assist device; LVEDV, le ventricular end-diastolic volume; LVEF, le ventricular ejection fraction; LVESD, le ventricular end-systolic diameter; LVH, le ventricular hypertrophy; MCS, mechanical circulatory support; MI, myocardial infarction; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; MRI, magnetic resonance imaging ; MV, mitral valve; NSAID, nonsteroidal anti-inflammatory drug ; NSVT, nonsustained ventricular tachycardia; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; NYHA, New York Heart Association; QALY, quality-adjusted life year; QOL, quality of life; PA, pulmonary artery; PASP, pulmonary artery systolic pressure; PCWP, pulmonary capillary wedge pressure; PET, positron emission tomography; PPAR-γ, peroxisome proliferator-activated receptor gamma; PUFA, polyunsaturated fatty acid; RA, right atrial; RAASi, renin-angiotensin-aldosterone system inhibitor; RCT, randomized controlled trial; RF, radiofrequency; RV, right ventricular; Rx, prescription; RVol, regurgitant volume; SCD, sudden cardiac death; SGLT2i, sodium-glucose cotransporter-2 inhibitors; SPECT, single photon emission CT; 99mTc-PYP, technetium pyrophosphate; TEE, transesophageal echocardiogram; TEER, transcatheter mitral edge-to-edge repair; TIA, transient ischemic attack; TTE, transthoracic echocardiogram; VA, ventricular arrhythmia; VF, ventricular fibrillation; VHD, valvular heart disease; VO 2 , oxygen consumption/oxygen uptake; VT, ventricular tachycardia

Articles in this issue

Links on this page

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Heart Failure - ACC AHA Heart Failure Guidelines 2022 Update